Valuation: Inhalation Sciences Sweden AB

Market Cap 1.14Cr 11.84L 10.36L 10L 9L 16.75L 11Cr 17.03L 44.84L 5.56Cr 44.47L 43.5L 19Cr P/E 2024
-12.8x
P/E 2025 -12.4x
Enterprise Value 85.86L 9L 8L 7L 7L 12.59L 8.49Cr 12.81L 33.72L 4.18Cr 33.44L 32.71L 14Cr EV / Sales 2024
5.6x
EV / Sales 2025 55x
Free-Float
94.25%
Yield 2024 *
-
Yield 2025 -
1 day+5.69%
1 week-5.51%
Current month-4.70%
1 month+9.31%
3 months-9.35%
6 months-51.10%
Current year-94.86%
1 week 0.2
Extreme 0.2
0.25
1 month 0.19
Extreme 0.194
0.25
Current year 0.17
Extreme 0.172
0.58
1 year 0.17
Extreme 0.172
0.58
3 years 0.17
Extreme 0.172
4.99
5 years 0.17
Extreme 0.172
11.3
10 years 0.17
Extreme 0.172
15.48
Manager TitleAgeSince
Chief Executive Officer - 16/09/2019
Chief Tech/Sci/R&D Officer - 01/01/2005
Corporate Officer/Principal - 02/06/2025
Director TitleAgeSince
Director/Board Member - 01/01/2005
Director/Board Member - 01/09/2022
Director/Board Member - 01/09/2024
Change 5-day change 1-year change 3-year change Capi.($)
+5.69%-5.51%-94.86%-92.06% 11.84L
+0.45%+0.69%+21.20%+1.50% 20TCr
-1.16%-4.51%-20.56%+19.96% 14TCr
+1.57%+0.57%-2.83%-16.25% 14TCr
-0.49%-0.82%-56.62%-14.64% 6.65TCr
+0.96%-2.29%+18.14%-0.25% 5.31TCr
+0.61%-1.09%-24.93%-30.81% 4.41TCr
+0.52%+2.75%+8.93%+13.34% 3.79TCr
-0.19%-0.75%+6.66%+42.84% 3.7TCr
0.00%-1.32%-13.88%-20.38% 2.94TCr
Average +0.80%-1.47%-15.88%-9.67% 7.49TCr
Weighted average by Cap. +0.27%-0.96%-3.92%+0.03%

Financials

2024 2025
Net sales 1.1Cr 11.46L 10.02L 9L 9L 16.2L 11Cr 16.48L 43.38L 5.38Cr 43.03L 42.09L 19Cr 30.41L 3L 3L 3L 2L 4L 3.01Cr 5L 11.94L 1.48Cr 11.84L 11.59L 5.1Cr
Net income -51.47L -5L -5L -4L -4L -8L -5.09Cr -8L -20.21L -2.51Cr -20.05L -19.61L -8.62Cr -1.02Cr -10.54L -9L -9L -8L -14.9L -10Cr -15.15L -39.9L -4.95Cr -39.57L -38.71L -17Cr
Net Debt -40.03L -4L -4L -3L -3L -6L -3.96Cr -6L -15.72L -1.95Cr -15.59L -15.25L -6.71Cr -28.31L -3L -3L -2L -2L -4L -2.8Cr -4L -11.12L -1.38Cr -11.03L -10.79L -4.74Cr
Logo Inhalation Sciences Sweden AB
Inhalation Sciences Sweden AB is a Sweden-based company, which develops and sells labtech equipment for inhalation research. The Company’s primary product is PreciseInhale, which is a laboratory system that lets scientists measure how inhaled particles act in lungs and affect human health. PreciseInhale is a dry powder aerosol research and development system, which generate aerosols and data of a quality. The system helps to eliminate poor candidate drugs before clinical trials. The secondary product is LaminarPace, a tool for drying small amounts of drug substance. The Company’s customers comprise Dow Chemical Group, Kings College London and Karolinska Institutet, among others. The Company’s main shareholder is Nordnet Pensionsforsakring.
Employees
5
Date Price Change Volume
10/26/10 SEK 0.2230 +5.69% 7,309
09/26/09 SEK 0.2110 -9.44% 68,090
08/26/08 SEK 0.2330 -4.90% 15,679
07/26/07 SEK 0.2450 +2.08% 925
06/26/06 SEK 0.2400 +1.69% 1,84,091

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ISAB Stock